By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Breast Cancer. According to news originating from Montpellier, France, by NewsRx correspondents, research stated, "Patients with locally advanced breast cancer treated with neoadjuvant chemotherapy are at risk of cancer treatment-induced bone loss and consequently of increased skeletal morbidity. In addition, this situation could be worsened by the fact that only a minority of patients with breast cancer have sufficient vitamin D."
Our news journalists obtained a quote from the research, "A comprehensive evaluation of bone homeostasis is critical in this context. We retrospectively evaluated the serum levels of calcium, vitamin D, TRAIL, RANK ligand (RANKL), Osteoprotegerin (OPG), Bone TRAP, CrossLaps and DKK1 in 77 patients (median age: 50 years; range 25-74), with locally advanced breast cancer treated in our institute with anthracyclines-taxane neoadjuvant chemotherapy (7 cycles of 21 days/each) between March 2007 and August 2008. Serum samples were collected before the first (baseline) and the last treatment cycle. Variations and correlations between biomarker levels were evaluated. At baseline, 79.5 % of patients had vitamin D insufficiency (<30 ng/ml), increasing to 97.4 % at the end of the neoadjuvant chemotherapy (p <0.0001). Calcium and RANKL serum concentrations were also significantly decreased, while OPG was significantly increased, resulting in lower RANKL/OPG ratio. Calcium and vitamin D, RANKL and vitamin D and RANKL and OPG levels were significantly correlated (Spearman's coefficient r=0.2721, p=0.0006; r=0.1916, p=0.002; and r=-0.179, p=0.03, respectively). Nearly all included patients suffered from vitamin D insufficiency by the end of the neoadjuvant chemotherapy with changes in the calcium/RANKL/OPG axis that are evocative of deregulation of a functional regulatory mechanism."
According to the news editors, the research concluded: "Further studies are needed to determine how drugs modulate this regulatory mechanism to preserve bone homeostasis in patients with breast cancer."
For more information on this research see: Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2012;134(2):709-17. Breast Cancer Research and Treatment can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Breast Cancer Research and Treatment - www.springerlink.com/content/0167-6806/)
The news correspondents report that additional information may be obtained from W. Jacot, Departement d'Oncologie Medicale, CRLC Val d'Aurelle-Paul Lamarque, 208, rue des Apothicaires, 34298 Montpellier, France (see also Breast Cancer).
The publisher's contact information for the journal Breast Cancer Research and Treatment is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Drugs, France, Europe, Oncology, Treatment, Montpellier, Chemotherapy, Bone Research, Breast Cancer, Women's Health.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.